Y Intercept Invests $91,000 in Actinium Pharmaceuticals Shares

Y Intercept Hong Kong Ltd has acquired a new stake in Actinium Pharmaceuticals, Inc., purchasing 64,909 shares valued at approximately $91,000 during the second quarter of 2023, according to a report from HoldingsChannel.com. This investment reflects growing interest in the biopharmaceutical company’s innovative treatments, particularly in the oncology sector.

Several other institutional investors have also made notable adjustments to their holdings in Actinium Pharmaceuticals. For instance, AQR Capital Management LLC significantly increased its stake by 278.6% in the first quarter, now holding 63,249 shares valued at $102,000 after acquiring an additional 46,545 shares. Callan Family Office LLC entered the fray with a new investment worth $38,000, while Nuveen LLC added a new position valued at $239,000 during the same period.

Another major player, Invesco Ltd., boosted its position in Actinium Pharmaceuticals by a staggering 1,135.9%, now owning 153,555 shares worth $247,000 after purchasing an additional 141,130 shares. Additionally, Gagnon Securities LLC also acquired a new position valued at $365,000. Overall, institutional investors and hedge funds own approximately 27.50% of Actinium Pharmaceuticals’ stock.

Stock Performance and Market Outlook

As of the latest trading session, shares of Actinium Pharmaceuticals, listed on the NYSE under the ticker symbol ATNM, opened at $1.26. The company has a market capitalization of $39.31 million, with a price-to-earnings ratio of -0.91 and a beta of -0.25. Over the past 52 weeks, the stock has fluctuated between a low of $1.03 and a high of $2.41. The company’s fifty-day moving average stands at $1.55, while the two-hundred day moving average is $1.58.

Actinium Pharmaceuticals focuses on developing targeted radiotherapies and antibody radiation conjugates aimed at improving treatment outcomes for patients who have not responded to existing oncology therapies. One of its flagship products, Iomab-B, serves as an induction and conditioning agent prior to bone marrow transplants for patients with relapsed and refractory acute myeloid leukemia (r/r AML).

Investors interested in following the latest developments and activities of hedge funds in Actinium Pharmaceuticals can access the most recent 13F filings and insider trades through HoldingsChannel.com.